Results 101 to 110 of about 2,146,220 (244)
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
Opportunistic Infection in HIV Patients at Tertiary Care Hospital in Rawalpindi
Objective: To determine the spectrum of opportunistic infection in human immunodeficiency virus patients at tertiary care hospital. Study Design: Cross-sectional study.
Mirza Waseem Javed +5 more
doaj +1 more source
Lenacapavir initiation with concomitant primidone: A case report with therapeutic drug monitoring
Lenacapavir (LEN), a first‐in‐class capsid inhibitor, has unique pharmacokinetics that enable twice‐yearly dosing. LEN is not extensively metabolized, although it is a substrate of CYP3A4, which introduces drug–drug interactions concerns. As adoption and implementation of LEN for treatment and prevention increase, additional guidance on concomitant ...
Aaron S. Devanathan +6 more
wiley +1 more source
The Opportunistic approach to monetary policy and financial markets [PDF]
We test the concept of the Opportunistic Approach to monetary policy in South Africa post 2000 inflation targeting regime. Our findings support the two features of the opportunistic approach.
Ruthira Naraidoo, Kasai Ndahiriwe
core
Lenacapavir is a first‐in‐class HIV‐1 capsid inhibitor with long‐acting pharmacokinetics that enable 6‐monthly subcutaneous dosing after initiation with oral lead‐in. Lenacapavir is a CYP3A4, UGT1A1 and P‐gp substrate; inducers of these enzymes and P‐gp can significantly decrease lenacapavir concentrations. In patients receiving lenacapavir for HIV pre‐
Mark McIntyre +6 more
wiley +1 more source
Long‐acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) is subject to clinically significant drug–drug interactions with strong enzyme inducers such as rifampicin due to markedly reduced drug exposure and potential development of resistance. However, real‐world evidence on managing this interaction remains scarce.
Lorenzo Ciullini +3 more
wiley +1 more source
LSPR biosensing enables rapid, sensitive, and low‐sample‐volume detection of biomarkers, with broad applications in diagnosing cancer, infectious, and chronic diseases. Advances in nanostructure design, micro/nanofabrication, and microfluidic integration have expanded the potential of LSPR sensors in biomedical diagnostics.
Zhaoxin Geng +4 more
wiley +1 more source
Mycobacterium avium-intracellulare infection during HIV disease: persisting problems
Overview of residual and novel problems in the management of Mycobacterium avium intracellulare opportunistic infections in the setting of HIV infection and ...
MANFREDI, ROBERTO
core
Oral microbial homeostasis, a dynamic host‐microbe balance, is vital in infectious diseases. Conventional antibiotics often disrupt this homeostasis, spurring interest in nanomaterials for oral microbial homeostasis rebalancing. This review outlines nanomaterial strategies across three ecological levels (population/community, ecosystem, and cross ...
Chen Hu +10 more
wiley +1 more source

